Ximelagatran

Base Information

• Chemical Name: Ximelagatran
• CAS No.: 192939-46-1
• Molecular Formula: C24H35 N5 O5
• Molecular Weight: 473.57
• DSSTox Substance ID: DTXSID5049075
• Wikipedia: Ximelagatran
• NCI Thesaurus Code: C77996
• Pharos Ligand ID: ZBJ1T8FPR1R5
• Metabolomics Workbench ID: 43643
• Mol file: 192939-46-1.mol

Synonyms:Exanta;glycine, N-((1)1-cyclohexyl-2-((2)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester;glycine, N-((1R)1-cyclohexyl-2-((2S)-((((4-(amino(hydroxyimino)methyl)phenyl)methyl)amino)carbonyl)-1-azetidinyl)2-oxoethyl)-ethyl ester;H 376 95;H 376-95;xi-melagatran;ximelagatran

Chemical Property of Ximelagatran

Chemical Property:

• Melting Point: 65-68?C
• Boiling Point: °Cat760mmHg
• PKA: 6.87±0.69(Predicted)
• Flash Point: °C
• PSA: 143.85000
• Density: 1.35g/cm³
• LogP: 2.51980
• Storage Temp.: -20°C Freezer, Under Inert Atmosphere
• XLogP3: 2.2
• Hydrogen Bond Donor Count: 4
• Hydrogen Bond Acceptor Count: 7
• Rotatable Bond Count: 11
• Exact Mass: 473.26381923
• Heavy Atom Count: 34
• Complexity: 731

Purity/Quality:

98%,99%, ^*data from raw suppliers

Ximelagatran ^*data from reagent suppliers

Safty Information:

• Pictogram(s):  
• Hazard Codes: 

MSDS Files:

SDS file from LookChem

Useful:

• Canonical SMILES: CCOC(=O)CNC(C1CCCCC1)C(=O)N2CCC2C(=O)NCC3=CC=C(C=C3)C(=NO)N
• Isomeric SMILES: CCOC(=O)CN[C@H](C1CCCCC1)C(=O)N2CC[C@H]2C(=O)NCC3=CC=C(C=C3)/C(=N/O)/N
• Recent ClinicalTrials: Long Term Open Follow-up With H376/95 vs. Warfarin
• Recent EU Clinical Trials: The 'EXTEND' study: A randomized, double-blind, parallel-group, phase IIIb, multi-centre study evaluating extended prophylactic treatment with melagatran/ximelagatran versus enoxaparin for the prevention of venous thromboembolic events in patients undergoing elective hip replacement or hip fracture surgery.
• Description: Ximelagatran, a prodrug of melagatran with improved oral bioavailability, is a direct thrombin inhibitor that was launched for the prevention of venous thromboembolic events (VTE) in elective hip or knee replacement surgery in Germany with several European countries following with approval for the same indication. A mutual recognition European filing was subsequently submitted for the prevention of stroke and other thromboembolic complications associated with atrial fibrillation (AF). While studies indicate that ximelagatran is as effective as traditional therapies for preventing strokes and recurring blood clots, the U.S. Food and Drug Administration has currently declined approval due to potential hepatotoxicity. Elevation of alanine aminotransferase (three times the upper limit of normal) has been observed in the first four months of therapy, but levels regress to normal upon discontinuation of the drug. Despite the questions surrounding the toxicological consequences of this elevated liver enzyme, ximelagatran remains an attractive alternative to the current antithrombotic therapies that utilize either the low molecular weight heparin (LMWH) or warfarin. Since LMWH is administered subcutaneously once or twice daily, the oral agent ximelagatran is preferable for patient compliance. In addition to the convenience of oral therapy, ximelagatran does not require the frequent laboratory monitoring and dosage adjustment that is necessary with warfarin treatment. A clinical study comparing the efficacy of a fixed dose (36 mg b.i.d.) of ximelagatran with adjusted dose warfarin for stroke prevention in patients with nonvalvular atrial fibrillation concluded that ximelagatran is not inferior to warfarin, and major bleeding occurred at rates similar to warfarin. The synthesis route to ximelagatran involves the coupling of the three major components, cyclohexylglycine, azetidine-2-carboxylic acid, and protected p-amidinobenzylamine, using solution-phase peptide chemistry. Subsequent alkylation of the N-terminus with ethyl bromoacetate, followed by deprotection of the amidine group and conversion to hydroxyamidine affords the double prodrug of melagatran. Delivery as ximelagatran provides reproducible oral bioavailability (18–25%), as measured by concentrations of the active metabolite melagatran formed by hydrolysis of the ethyl ester and dehydroxylation of the amidine. Melagatran reversibly binds to the arginine side pocket of both free and clot-bound thrombin (Ki=2 nM). Inhibition of thrombin ultimately blocks the conversion of fibrinogen to fibrin, the final step of the coagulation process. A linear relationship between ximelagatran dose and melagatran concentration exists with peak concentrations observed two to three hours post dose. Renal excretion is the primary route of elimination of melagatran (80%) with a half-life of 3–5 hours. Furthermore, the pharmacokinetics of ximelagatran is not influenced by the type of thromboembolic disease, obesity, ethnicity, gender, or age. In addition to the typical contraindications of current antithrombotic therapies, the increase in the liver enzyme alanine aminotransferase suggests that ximelagatran should not be used in patients with creatine clearance ＜30 mL/min. pending further study in this population. While ximelagatran does not appear to have any interactions with the cytochrome P-450 system, combination with aspirin has been shown to increase adverse bleeding. Ximelagatran is an ester prodrug of melagatran, a potent, direct, and reversible thrombin inhibitor (Ki = 1.2 nM). While melagatran has poor oral bioavailability, ximelagatran displays good bioavailability resulting, in part, from rapid absorption at the gastrointestinal tract, as well as rapid onset of action. Ximelagatran is converted to melagatran by reduction and hydrolysis at the liver and other tissues. It is used as an anticoagulant in a variety of situations, including thromboembolic disorders, stroke prevention in atrial fibrillation, and therapy in vein thrombosis.
• Uses: An orally active direct thrombin inhibitor; prodrug of Melagatran. Antithrombotic. An orally active direct thrombin inhibitor; prodrug of Melagatran. Antithrombotic